Efficacy and Tolerability of Moxifloxacin in Patients with Respiratory Tract Infections Treated in General Practice: Results of a Post-marketing Surveillance Study

Overview

Journal Clin Drug Investig

Date 2006 Dec 14

PMID 17163283

Citations 2

Authors

Weiqiang Chen

Changgui Wu

Zhikui Li

Changqing Bai

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to assess the efficacy, safety and tolerability of oral moxifloxacin in patients with respiratory tract infections (RTIs) treated by attending physicians in routine clinical practice in China.

Methods: This was an open-label, prospective, uncontrolled, post-marketing surveillance study that was undertaken between November 2002 and July 2003. Altogether, 855 patients with RTIs were treated with moxifloxacin. Data were collected by 257 physicians throughout China. Symptoms of RTI (fever, cough, purulent sputum, dyspnoea, thoracic pain, nasal obstruction, nasal secretion and headache), together with auscultatory findings, were assessed at baseline and at follow-up visits, and classified as 'absent', 'mild' or 'severe' by the attending physician.

Results: Moxifloxacin produced significant improvements in 70.7% of patients after only 3 days of treatment. In 91.7% of patients, symptoms were improved after 5 days of treatment; 76.1% of patients recovered after 7 days and 84.7% recovered after 10 days of treatment. The mean +/- SD time until recovery was 5.1 +/- 2.6 days. Assessment of treatment efficacy by the physicians was 'good' or 'very good' for 89.2% of patients. In 87.3% of cases, physicians rated patients' acceptance of therapy with moxifloxacin as 'good' or 'very good'. The tolerability of moxifloxacin therapy was rated as 'good' or 'very good' for 88.8% of patients. Very few adverse events (4.1% of patients) were reported with moxifloxacin; most of them involved mild CNS disorders and gastrointestinal disturbances.

Conclusions: Moxifloxacin was shown to be an effective and well tolerated treatment for this group of patients with RTIs and was highly rated by both physicians and patients because of rapid symptom improvement and good tolerability.

Citing Articles

Gender analysis of moxifloxacin clinical trials.

Chilet-Rosell E, Ruiz-Cantero M, Pardo M J Womens Health (Larchmt). 2013; 23(1):77-104.

PMID: 24180298 PMC: 3881443. DOI: 10.1089/jwh.2012.4171.

Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Van Bambeke F, Tulkens P Drug Saf. 2009; 32(5):359-78.

PMID: 19419232 DOI: 10.2165/00002018-200932050-00001.

References

Krasemann C, Meyer J, Tillotson G . Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis. 2001; 32 Suppl 1:S51-63. DOI: 10.1086/319377. View

Epstein B, Gums J . Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy. Drugs. 2005; 65(14):1949-71. DOI: 10.2165/00003495-200565140-00004. View

Malangoni M, Song J, Herrington J, Choudhri S, Pertel P . Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006; 244(2):204-11. PMC: 1602153. DOI: 10.1097/01.sla.0000230024.84190.a8. View

Sethi S . Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000; 117(5 Suppl 2):380S-5S. DOI: 10.1378/chest.117.5_suppl_2.380s. View

Lode H, Lubasch A, Raffenberg M, Mauch H . Clinical results in the treatment of respiratory infections with moxifloxacin. Drugs Today (Barc). 2003; 36(4):245-53. DOI: 10.1358/dot.2000.36.4.570202. View

Wilson R, Allegra L, Huchon G, Izquierdo J, Jones P, Schaberg T . Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004; 125(3):953-64. DOI: 10.1378/chest.125.3.953. View

Song J, Jung S, Ki H, Shin M, Ko K, Son J . Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis. 2004; 38(11):1570-8. DOI: 10.1086/420821. View

Aydemir S, Tunger A, Cilli F . In vitro activity of fluoroquinolones against common respiratory pathogens. West Indian Med J. 2006; 55(1):9-12. DOI: 10.1590/s0043-31442006000100003. View

CHODOSH S, DeAbate C, Haverstock D, Aneiro L, Church D . Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med. 2000; 94(1):18-27. DOI: 10.1053/rmed.1999.0708. View

10.

Petitpretz P, Arvis P, Marel M, Moita J, Urueta J . Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 2001; 119(1):185-95. DOI: 10.1378/chest.119.1.185. View

11.

Finch R, Schurmann D, Collins O, KUBIN R, McGivern J, Bobbaers H . Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002; 46(6):1746-54. PMC: 127227. DOI: 10.1128/AAC.46.6.1746-1754.2002. View

12.

Apisarnthanarak A, Mundy L . Etiology of community-acquired pneumonia. Clin Chest Med. 2005; 26(1):47-55. PMC: 7119140. DOI: 10.1016/j.ccm.2004.10.016. View

13.

Gwaltney Jr J . Acute community-acquired sinusitis. Clin Infect Dis. 1996; 23(6):1209-23; quiz 1224-5. PMC: 7109987. DOI: 10.1093/clinids/23.6.1209. View

14.

Stass H, Kubitza D . Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet. 2001; 40 Suppl 1:63-70. DOI: 10.2165/00003088-200140001-00009. View

15.

Blondeau J, Laskowski R, Bjarnason J, Stewart C . Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents. 2000; 14(1):45-50. DOI: 10.1016/s0924-8579(99)00143-0. View

16.

Guthrie R . Community-acquired lower respiratory tract infections: etiology and treatment. Chest. 2001; 120(6):2021-34. DOI: 10.1378/chest.120.6.2021. View

17.

Landen H, Moller M, Tillotson G, KUBIN R, Hoffken G . Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res. 2001; 29(2):51-60. DOI: 10.1177/147323000102900202. View

18.

Liu Y, Chen M, Zhao T, Wang H, Wang R, Liu Q . [A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China]. Zhonghua Jie He He Hu Xi Za Zhi. 2006; 29(1):3-8. View

19.

Ulrich M, Berger J, Moller J, DORING G . Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro. Infection. 2006; 33 Suppl 2:50-4. DOI: 10.1007/s15010-005-8208-9. View

20.

Barth J, Landen H . Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis. Clin Drug Investig. 2013; 23(1):1-10. DOI: 10.2165/00044011-200323010-00001. View